Supernus Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Supernus Pharmaceuticals (SUPN).

Price Target Range — 7 Quarters

Analyst Consensus — 5 Analysts

4Buy

1Hold

Consensus RatingOverweight# Analysts5Avg. Consensus PT$62Upside to Avg. PT+42.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 9, 2026	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$63→$67
Dec 19, 2025	Stifel	Annabel Samimy	PT Raise	Hold	$50→$55
Oct 29, 2025	B of A Securities	Pavan Patel	Initiate	Buy	$65
Oct 23, 2025	TD Cowen	Stacy Ku	PT Raise	Buy	$45→$60
Oct 9, 2025	Piper Sandler	David Amsellem	Upgrade	Neutral→Overweight	$40→$65
Sep 30, 2025	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$46→$63
Aug 29, 2025	Piper Sandler	David Amsellem	PT Raise	Neutral	$36→$40
Aug 6, 2025	Cantor Fitzgerald	Kristen Kluska	PT Raise	Overweight	$42→$46
Feb 26, 2025	Cantor Fitzgerald	Kristen Kluska	Maintained	Neutral	$36
Feb 19, 2025	Cantor Fitzgerald	Kristen Kluska	Downgrade	Overweight→Neutral	$57→$36
Sep 11, 2024	Piper Sandler	David Amsellem	Downgrade	Overweight→Neutral	$41→$36
Feb 28, 2024	Piper Sandler	David Amsellem	PT Cut	Overweight	$45→$41
Nov 9, 2023	Piper Sandler	David Amsellem	PT Raise	Overweight	$42→$43
Oct 25, 2023	Piper Sandler	David Amsellem	PT Cut	Overweight	$43→$42

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67

Cantor Fitzgerald analyst Kristen Kluska maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Overweight and raises the price target from $63 to $67.

Benzinga Newsdesk

PRO
Stifel Maintains Hold on Supernus Pharmaceuticals, Raises Price Target to $55

Stifel analyst Annabel Samimy maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Hold and raises the price target from $50 to $55.

Benzinga Newsdesk

PRO
B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65

B of A Securities analyst Pavan Patel initiates coverage on Supernus Pharmaceuticals (NASDAQ:SUPN) with a Buy rating and announces Price Target of $65.

Benzinga Newsdesk

Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)

Benzinga Insights

PRO
TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60

TD Cowen analyst Stacy Ku maintains Supernus Pharmaceuticals (NASDAQ:SUPN) with a Buy and raises the price target from $45 to $60.

Benzinga Newsdesk

Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday

Avi Kapoor

Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67

PRO
Stifel Maintains Hold on Supernus Pharmaceuticals, Raises Price Target to $55

PRO
B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65

Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)

PRO
TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60

Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday

People Also Watch

People Also Watch

Benzinga

Benzinga

Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROCantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67

PROStifel Maintains Hold on Supernus Pharmaceuticals, Raises Price Target to $55

PROB of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65

Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)

PROTD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60

Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday

People Also Watch

People Also Watch

PRO
Cantor Fitzgerald Maintains Overweight on Supernus Pharmaceuticals, Raises Price Target to $67

PRO
Stifel Maintains Hold on Supernus Pharmaceuticals, Raises Price Target to $55

PRO
B of A Securities Initiates Coverage On Supernus Pharmaceuticals with Buy Rating, Announces Price Target of $65

PRO
TD Cowen Maintains Buy on Supernus Pharmaceuticals, Raises Price Target to $60